Marietta Wealth Management LLC Raises Stake in Thermo Fisher Scientific Inc. $TMO

Marietta Wealth Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 16,399 shares of the medical research company’s stock after purchasing an additional 1,007 shares during the period. Marietta Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $6,649,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Simplicity Wealth LLC lifted its holdings in Thermo Fisher Scientific by 56.5% in the second quarter. Simplicity Wealth LLC now owns 2,273 shares of the medical research company’s stock valued at $922,000 after acquiring an additional 821 shares during the period. OLD National Bancorp IN lifted its holdings in Thermo Fisher Scientific by 6.8% in the second quarter. OLD National Bancorp IN now owns 42,802 shares of the medical research company’s stock valued at $17,354,000 after acquiring an additional 2,738 shares during the period. Capital City Trust Co. FL lifted its holdings in Thermo Fisher Scientific by 0.3% in the second quarter. Capital City Trust Co. FL now owns 10,636 shares of the medical research company’s stock valued at $4,312,000 after acquiring an additional 36 shares during the period. Tandem Investment Partners LLC lifted its holdings in Thermo Fisher Scientific by 17.6% in the second quarter. Tandem Investment Partners LLC now owns 1,821 shares of the medical research company’s stock valued at $738,000 after acquiring an additional 273 shares during the period. Finally, Talbot Financial LLC lifted its holdings in Thermo Fisher Scientific by 40.8% in the second quarter. Talbot Financial LLC now owns 24,499 shares of the medical research company’s stock valued at $9,933,000 after acquiring an additional 7,097 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 3.6%

Shares of TMO stock opened at $543.88 on Friday. The stock’s fifty day moving average is $482.58 and its two-hundred day moving average is $447.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $205.37 billion, a P/E ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. Barclays increased their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, HSBC reiterated a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $585.37.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last three months. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.